Pharma heart failure market to rise by £5.8bn

The heart failure market is set to rise by £5.8bn ($8.6bn) within the next century, according to GlobalData

Research and consulting firm, GlobalData, said that the heart failure market is set to rise from around £2.18bn ($3.2bn) in 2015 to £8bn ($11.8bn) by 2025, representing a compound annual growth rate of 13.7%.

The company’s latest report states that the key drivers of this substantial growth, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be the launch of Novartis’ first-in-class drug, Entresto, and several acute heart failure add-on therapies, as well as an increase in the global prevalence of chronic heart failure.

Elizabeth Hamson, GlobalData’s analyst covering cardiovascular and metabolic disorders, explains: “Novartis’ Entresto is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNi), which was launched in the US in 2015 and the five European countries in 2016, and is set for release in Japan by 2020.

“Entresto has struggled to penetrate the chronic heart failure market, achieving dismal sales in the US since its launch in July 2015.

“GlobalData has identified high pricing and the general reluctance of cardiologists and physicians to adopt new therapies as the main barriers to the uptake of this drug.

“Despite this, it is expected that Entresto will begin to dominate the global heart failure space, particularly after its label expansion to heart failure with preserved ejection fraction, which is expected to occur in 2020, making it the strongest driver of market growth.”

Despite these significant advances for chronic heart failure, particularly with reduced ejection fraction, there have been no advances in the treatment of acute heart failure for the past two decades. However, two drugs currently undergoing Phase III evaluation for the treatment of acute heart failure have the potential to shape how this condition is treated, according to GlobalData.

Hamson continues: “Cardiorentis’ ularitide and Novartis’ serelaxin represent novel and exciting treatment options for acute heart failure.

“Both are recombinant forms of human proteins that are intended to be used on top of the current standard-of-care for acute heart failure, intravenous administered loop diuretics.

“While the heart failure market will be invigorated by exciting new therapies over the forecast period, there will remain a major unmet need in the lack of a therapy which can reverse disease progression, rather than merely slowing it down.

“In this way, GlobalData believes that the scope for the development of even better and more exciting heart failure drugs is still very broad.”